Stockreport

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar [Yahoo! Finance]

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 months, compared to SOC at 4 mo [Read more]